ADICON HOLDINGS (09860) experienced a significant intraday surge of nearly 17%. At the time of writing, the stock was up 15.58%, trading at HK$4.97, with a turnover of HK$5.5148 million. Market sentiment towards the company had been negative since November 2025, when ADICON HOLDINGS announced a $204 million acquisition of Crown Bioscience. This, combined with expectations of its removal from the Stock Connect program, led to a period of adjustment in its share price. Notably, this short-term volatility has created an opportunity for the market to reassess the company's intrinsic value. On March 9th, with the negative impact of the Stock Connect removal now fully priced in, a return of capital is anticipated to drive a valuation recovery for the stock. Furthermore, the current market capitalization of Crown Bioscience's peer, BioMap, has reached HK$27 billion, indicating that ADICON's present valuation does not fully reflect its reasonable worth and suggests ample room for subsequent upward correction.